Pharma News

Sun Pharmaceutical Industries Ltd and includes its subsidiaries and/or associate companies) has announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).

Eminence Business Media  organized the Pharma GMP, GCP & Quality Management Webinar on  May 14th-15th, 2020.

Patients with a vascular condition called abdominal aortic aneurysm did not benefit from taking the common antibiotic doxycycline for two years to shrink the aneurysm when compared to those who took a placebo, according to a Vanderbilt University Medical Center (VUMC) study published in the Journal of the American Medical Association (JAMA).

Loss of smell (anosmia) and changes in taste (dysgeusia) were strongly associated with SARS-CoV-2, according to a Canadian study published in CMAJ (Canadian Medical Association Journal).

A potential blood-based biomarker for Alzheimer's and other neurodegenerative diseases seems even more promising thanks to new research from a Massachusetts General Hospital-led study. According to this team's work, neurofilament light chain (NfL) has great potential as a biomarker for early detection of Alzheimer's disease and could be also useful for monitoring treatment response for that condition.

Giving beneficial bacteria to stressed mothers during the equivalent of the third trimester of pregnancy prevents an autism-like disorder in their offspring, according to a new animal study by University of Colorado Boulder researchers.

Caption : Human intestine, engineered in the laboratory of Tracy Grikscheit, MD.

Babies with Hirschsprung's disease are born with an incomplete or absent gut nervous system. Children's Hospital Los Angeles investigator Tracy Grikscheit, MD, runs a laboratory that investigates the therapeutic potential of tissue engineering - the induced growth of healthy tissue using stem cells. In a new study, Dr. Grikscheit successfully grew a fully functional gut nervous system - or ENS - in a pre-clinical model. While not yet available clinically, the finding brings surgeons like Dr. Grikscheit one step closer to helping babies in need.

Caption : Nicotine induced defects in the frog embryo brain (center) can be rescued by transplanting an HCN2 expressing patch on the embryo far from the brain. Treated embryos are observed to have normal brain morphology and function (right). View of normal embryo head is shown at left. Similar results are seen when nicotine-exposed embryos are treated with ionoceutical drugs. (FB = forebrain; MB = midbrain; HB = hindbrain)

Researchers led by biologists at Tufts University have discovered that the brains of developing frog embryos damaged by nicotine exposure can be repaired by treatment with certain drugs called "ionoceuticals" that drive the recovery of bioelectric patterns in the embryo, followed by repair of normal anatomy, gene expression and brain function in the growing tadpole. The research, published today in Frontiers in Neuroscience, introduces intervention strategies based on restoring the bioelectric "blueprint" for embryonic development, which the researchers suggest could provide a roadmap for the exploration of therapeutic drugs to help repair birth defects.